

## EVOTEC AG

ISIN: DE0005664809

WKN: 566480

## Overview

2024/04/29 10:20:28

Price

9.575 EUR

Difference



3.68% (0.34)

## General attributes

ISIN DE0005664809

Symbol EVT

Exchange Xetra

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 1,637 EUR

Benchmark GERMANY DAX

## Market data

Bid (Bid size) 9.555 EUR (1,343)

Ask (Ask size) 9.58 EUR (3,689)

Open 9.55 EUR

High 9.695 EUR

Low 9.355 EUR

Close (prev. day) 9.235 EUR

VWAP 9.52941 EUR

Volume (pcs) 560,434

Trading volume 5,340,608.04

Number of trades 1,591

Last size 294

## Futures and Options

Related Futures 23

Related Options -

## PDF Downloads

Company report: EVOTEC AG



5Y



Information about previous performance does not guarantee future performance.

Source: FactSet

## Recent research

on sector		on market	
Date		Headline	Download
2024/04/26		Global Equity Ratings	
2024/04/03		Global Equity Ratings	
2024/03/13		Global Equity Ratings	
2024/02/22		Global Equity Ratings	
2024/02/14		Global Equity Ratings	

## Details

2024/04/29 10:20:28

## Price

9.575 EUR

Difference ▲ 3.68% (0.34)

## General attributes

ISIN DE0005664809

Symbol EVT

Exchange Xetra

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 1,637 EUR

Benchmark GERMANY DAX

## Market data

Bid (Bid size) 9.555 EUR (1,343)

Ask (Ask size) 9.58 EUR (3,689)

Open 9.55 EUR

High 9.695 EUR

Low 9.355 EUR

Close (prev. day) 9.235 EUR

VWAP 9.52941 EUR

Volume (pcs) 560,434

Trading volume 5,340,608.04

Number of trades 1,591

Last size 294

## Performance and Risk

	6m	1Y	3Y
Perf (%)	-44.98%	-43.22%	-72.94%
Perf (abs.)	-7.55	-7.03	-24.90
Beta	2.29	1.56	1.06
Volatility	77.28	62.74	52.09

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Price data

Ø price 5 days   Ø volume 5 days (pcs.)	11.183 EUR (6,683,788)
Ø price 30 days   Ø volume 30 days (pcs.)	13.252 EUR (1,721,195)
Ø price 100 days   Ø volume 100 days (pcs.)	15.220 EUR (1,062,641)
Ø price 250 days   Ø volume 250 days (pcs.)	18.120 EUR (688,670)
YTD High   date	21.420 EUR (2024/01/03)
YTD Low   date	8.520 EUR (2024/04/24)
52 Weeks High   date	24.440 EUR (2023/07/25)
52 Weeks Low   date	8.520 EUR (2024/04/24)

## All listings for EVOTEC AG

Exchange <span style="color: blue;">⊕</span>	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/04/29	10:20	9.575 EUR	5.34	1,591
Vienna Stock Exchange	2024/04/29	09:05	9.44 EUR	0.00	1
Tradegate	2024/04/29	10:21	9.56 EUR	3.41	444
Stuttgart	2024/04/29	10:19	9.585 EUR	0.28	43
SIX Swiss Exchange	2023/	17:35	27.76 CHF	0.00	1

	04/12					
Munich	2024/ 04/29	09:12	9.395	EUR	0.00	3
London Stock Exchange European Trade Reporting	2024/ 04/29	09:32	9.51	EUR	0.00	4
Hanover	2024/ 04/29	08:16	9.505	EUR	0.00	1
Hamburg	2024/ 04/29	09:49	9.47	EUR	0.00	2
Frankfurt	2024/ 04/29	10:13	9.58	EUR	0.02	6
FINRA other OTC Issues	2024/ 04/24	17:45	10.18	USD	0.01	3
Euronext Milan MTF Trading After Hours	2024/ 03/21	18:00	13.20	EUR	0.00	2
Euronext Milan MTF Global Equity Market	2024/ 04/29	09:52	9.63	EUR	0.01	6
Duesseldorf	2024/ 04/29	09:31	9.395	EUR	0.02	2
Berlin	2024/ 04/29	10:20	9.585	EUR	0.00	4

## Company profile

### Company Logo



### Contact Details

EVOTEC SE

--

Manfred Eigen Campus, Essener Bogen 7 -  
22419 Hamburg

Telefon: +49-40-56081-0

Fax: +49-40-56081-222

E-mail: [info@evotec.com](mailto:info@evotec.com)

### PDF Downloads

Company report: EVOTEC AG



### Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

### Members of Management Board

Mario Polywka	Chairman of Managing Board
Cord Dohrmann	Member of Executive Committee
Craig Johnstone	Member of Executive Committee
Matthias Evers	Member of Executive Committee
Laetitia Rouxel	Member of Executive Committee

### Board of directors

Iris Löw-Friedrich	Chairman of Supervisory Board
Constanze Ulmer-Eilfort	Member of Supervisory Board
Elaine Sullivan	Member of Supervisory Board
Camilla Languille	Member of Supervisory Board
Roland Sackers	Member of Supervisory Board